S. Ormarsdóttir

发表

An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis

R. Hultcrantz, H. Mallmin, T. Naessén, 2004, Journal of internal medicine.

Osteoporosis in Chronic Liver Disease

S. Ormarsdóttir, 2001 .

Increased rate of bone loss at the femoral neck in patients with chronic liver disease

K. Michaëlsson, H. Mallmin, Ö. Ljunggren, 2002, European journal of gastroenterology & hepatology.

Longitudinal bone loss in postmenopausal women with primary biliary cirrhosis and well‐preserved liver function

H. Mallmin, Ö. Ljunggren, R. Olsson, 2002, Journal of internal medicine.

Circulating levels of insulin-like growth factors and their binding proteins in patients with chronic liver disease: lack of correlation with bone mineral density.

W. Blum, H. Mallmin, Ö. Ljunggren, 2001, Liver.

Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis.

J. Goldhahn, J. Reginster, R. Rizzoli, 2008, Bone.

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science

J. Reginster, R. Rizzoli, A. Laslop, 2008, Osteoporosis International.

European regulatory perspectives for innovative therapies

J. Reginster, E. Abadie, S. Ormarsdóttir, 2008, Osteoporosis International.

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science

J. Reginster, R. Rizzoli, A. Laslop, 2008, Osteoporosis International.

[Hepatotoxicity associated with the use of Herbalife].

S. Olafsson, M. Jóhannsson, S. Ormarsdóttir, 2010, Laeknabladid.

Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort

Jiri Aubrecht, John-Michael Sauer, Simon Kirby, 2018, Hepatology.

Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies

A. Barton, J. Reginster, A. Laslop, 2011, Annals of the rheumatic diseases.

Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease.

H. Mallmin, O. Ljunggren, L. Lööf, 1999, Journal of hepatology.

Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA

N. Goel, J. Reginster, A. Laslop, 2011, Current medical research and opinion.

Causality Assessment for Suspected DILI During Clinical Phases of Drug Development

P. Watkins, G. Aithal, L. Seeff, 2014, Drug Safety.

Evaluation of in vivo immune complex formation and complement activation in patients receiving intravenous Streptokinase

S. Ormarsdóttir, J. Freysdottir, A. Sigfússon, 1993, Clinical and experimental immunology.

Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)

M. Hiligsmann, S. Silverman, O. Bruyère, 2023, Osteoporosis International.

Inverse relationship between circulating levels of leptin and bone mineral density in chronic liver disease

W. Blum, H. Mallmin, Ö. Ljunggren, 2001, Journal of gastroenterology and hepatology.